Instructions for reporting COVID-19 Adverse Events Following Immunization (AEFI) after the second dose

As the COVID-19 vaccination campaign progresses and more individuals receive their second doses, it is critical that PHAC is able to monitor adverse events following immunization for the following:

1. Mixed vaccines for first and second dose.
2. Time interval between the administered doses.
3. Seriousness of AEFIs following second dose.

Instructions for providing data related to previous dose(s) of COVID-19 Vaccines:

When completing an AEFI form for a second dose (or future immunizations/boosters) of a COVID-19 vaccine, please include the following for the previous dose(s) of COVID-19 immunization(s) in the following table in Section 4b. Medical history of the revised National AEFI Form:

1. Date of previous COVID-19 immunization;
2. Dose number;
3. Vaccine trade name; and
4. Vaccine manufacturer

<table>
<thead>
<tr>
<th>Date of previous immunization</th>
<th>Dose number</th>
<th>Vaccine trade name</th>
<th>Vaccine manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional information regarding previous dose-related AEFIs can be added to the Supplementary Information Section (10) of the National AEFI Report Form.

For Provinces and Territories who are not using the National AEFI form:

Please contact the VVWG secretariat (phac.vaccine.vigilance.aspc@canada.ca) and indicate where this information will be provided on your Provincial or Territorial specific AEFI form and PHAC will ensure that it is entered (or for those submitting electronically that it is mapped) into CAEFISSS appropriately.